Business Context and Reporting Period
Company: Context Therapeutics Inc. (CNTX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Context is a clinical-stage biopharmaceutical company developing T cell engaging (TCE) bispecific antibodies for solid tumors. Key product candidates include CTIM-76 (CLDN6 x CD3) and CT-202 (Nectin-4 x CD3). The company discontinued internal development of CT-95 (MSLN x CD3) in August 2026 to prioritize capital allocation for its lead assets.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(23.2) million | $(13.4) million |
| Net Loss Per Share (Basic & Diluted) | $(0.24) | $(0.14) |
| Research & Development Expenses | $19.5 million | $11.3 million |
| General & Administrative Expenses | $4.8 million | $4.0 million |
| Cash and Cash Equivalents (End of Period) | $43.0 million | $83.5 million |
| Net Cash Used in Operating Activities | $(18.4) million | $(10.9) million |
| Accumulated Deficit | $(154.1) million | $(108.2) million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately 73% year-over-year, driven primarily by higher R&D expenditures.
- R&D Expense Surge: R&D expenses rose by $8.3 million (73%) compared to the prior six-month period. This increase was largely due to a $6.5 million payment related to the BioAtla License Agreement Amendment for CT-202 and increased clinical trial costs for CTIM-76 and CT-202.
- Cash Burn: Cash and cash equivalents decreased by $23.0 million during the period, reflecting a net cash burn of $18.4 million from operations and $4.6 million from investing activities (primarily the BioAtla payment).
- Interest Income Decline: Interest income dropped by approximately 50% due to lower average cash balances.
Guidance, Outlook, and Risks
- Portfolio Prioritization: In August 2026, the company announced the discontinuation of CT-95 to focus resources on CTIM-76 and CT-202. CT-95 Phase 1 trial is being wound down.
- Clinical Milestones:
- CTIM-76: Received FDA Fast Track designation for platinum-resistant ovarian cancer. Phase 1a data presented in June 2026. Phase 1b expansion anticipated in Q1 2027.
- CT-202: First patient dosing expected in Q3 2026. Initial Phase 1a data expected in H2 2027.
- Liquidity Outlook: Management believes current cash of $43.0 million is sufficient to fund operations into the fourth quarter of 2027. Additional capital will be required thereafter.
- Financing: The company has an At-The-Market (ATM) facility with $75.0 million remaining available. No committed credit facilities exist.
- Key Risks:
- Nasdaq Compliance: Received notice in July 2026 of non-compliance with the minimum bid price requirement ($1.00) due to stock price closing below this threshold for 30 consecutive days. Compliance must be regained by January 25, 2027, to avoid delisting.
- Intellectual Property: Potential third-party patent claims regarding CTIM-76 technology.
- Capital Needs: Failure to secure additional financing could force delays or curtailment of operations.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that $43.0 million will sustain operations through Q4 2027, given the high burn rate.
- Nasdaq Status: Monitor stock price performance to ensure compliance with the $1.00 minimum bid price requirement by the January 2027 deadline.
- BioAtla Agreement: Confirm that the $6.5 million payment fully settled future milestone and royalty obligations for CT-202 as stated in the amendment.
- CT-95 Wind-down: Assess the timeline and cost implications of winding down the CT-95 Phase 1 trial.
- ATM Facility Usage: Track utilization of the $75.0 million ATM facility to gauge immediate capital raising activity.